Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCฮธ Inhibitor Preclinical Program from Aqilion AB
Acrivon Therapeutics, Inc. ACRV
$1.59
โฒ +0.63%
(+$0.01)
📅 Earnings This Week
Open
$1.58
Prev Close
$1.58
Day Range
$1.55 โ $1.65
52W Range
$1.27 โ $3.56
Market Cap
$67.71M
Beta
1.99
EPS (TTM)
$-1.88
๐ Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2022-11-15 |
| Shares Out. | 42,850,000 |
| Website | acrivon.com/ โ |
| Phone | 16172078979 |
| Employees | 76 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$18.0M |
| Free Cash Flow | -$64.1M |
| Total Assets | $99.1M |
| Total Liabilities | $12.4M |
| Equity | $86.7M |
About Acrivon Therapeutics, Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Acrivon Therapeutics, Inc. is a publicly traded company under the ticker symbol ACRV on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
๐ Analyst Ratings
13 analysts (2026-11-01)
๐ฐ Latest News for ACRV
Acrivon Therapeutics Acquires Janus Kinase 1 Inhibitor ACR-525 From Aqilion AB; Terms Undisclosed
Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium
Acrivon Therapeutics To Present Dose Escalation Data From Its Current Phase 1/2 Trial Of ACR-2316 At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics